Biotech Values

[dewophile]

I’ll leave comments about the lawsuit to the lawyers. My only observation is that companies that are more vulnerable to this legislation don’t seem to be trading at much if any discount to those that are more protected so either investors are confident pharma will effectively fight this or are not worried about a timeline beyond 4-5 years when this kicks into high gear (affecting more drugs including part B)